

Full list of publications

ORCID Identifier <https://orcid.org/0000-0002-6892-9751>

Original articles, peer-reviewed

1. **Steffens S**, Thiel H-J, Behrens S-E (1999). *The RNA-dependent RNA polymerases of different members of the family Flaviviridae exhibit similar properties in vitro*. *Journal of General Virology*, 80(Pt 10): 2583-90
2. **Steffens S**, Frank S, Fischer U, Heuser C, Meyer KL, Dobberstein K-U, Rainov NG, Kramm CM (2000). *EGFP fusion proteins of HSV-TK and cytochrome P450 4B1: Applications for prodrug-activating enzyme gene therapy*. *Cancer Gene Therapy*, 7(5): 806-12
3. Frank S, **Steffens S**, Fischer U, Heuser C, Rainov NG, Kramm CM (2002). *Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy*. *Cancer Gene Therapy*, 9(2): 178-88
4. Kramm CM, Korholz D, Rainov NG, Niehues T, Fischer U, **Steffens S**, Frank S, Banning U, Horneff G, Schrotten H, Burdach S (2002). *Systemic activation of the immune system during ganciclovir treatment following intratumoral herpes simplex virus type 1 thymidine kinase gene transfer in an adolescent ependymoma patient*. *Neuropediatrics*, 33(1): 6-9
5. **Steffens S**, Sandquist A, Frank S, Fischer U, Lex C, Rainov NG, Kramm CM (2004). *A neuroblastoma-selective suicide gene therapy approach using the tyrosine hydroxylase promoter*. *Pediatric Research*, 56(2): 268-7
6. Veillard NR, **Steffens S**, Burger F, Pelli G, Mach F (2004). *Differential expression patterns of pro- and anti-inflammatory mediators during atherogenesis in mice*. *Arteriosclerosis, Thrombosis and Vascular Biology*, 24(12):2339-44
[6.368]
7. Sena-Esteves M, Tebbets J, **Steffens S**, Crombleholme T, Flake A (2004). *Optimized large-scale production of high titer lentivirus vector pseudotypes*. *Journal of Virological Methods*, 122(2):131-9
8. **Steffens S**, Tebbets J, Kramm CM, Flake A, Sena-Esteves M (2004). *Transduction of human glial and neuronal tumor cells with different lentivirus vector pseudotypes*. *Journal of Neuro-Oncology*, 70(3):281-8
9. Fischer U, **Steffens S**, Frank S, Rainov NG, Schulze-Osthoff K, Kramm CM (2005). *Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells*. *Oncogene*, 24(7):1231-43
10. Arnaud C, Burger F, **Steffens S**, Veillard N, Nguyen TH, Trono D, Mach F (2005). *Statins reduce C-Reactive Protein in hepatocytes: New evidence for anti-inflammatory effects of statins*. *Arteriosclerosis, Thrombosis and Vascular Biology*, 25(6):1231-6

11. **Steffens S**, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F (2005). *Low dose oral cannabinoid-therapy reduces progression of atherosclerosis in mice*. *Nature*, 434(7034):782-6
12. Veillard NR, **Steffens S**, Pelli G, Lu GB, Kwak BR, Gerard C, Charo IF, Mach F (2005). *Differential influence of the chemokine receptors CCR2 and CXCR3 in the development of atherosclerosis in vivo*. *Circulation*, 112(6):870-8
13. Veillard NR, Braunersreuther V, Arnaud C, Burger F, Pelli G, **Steffens S**, Mach F (2006). *Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages*. *Atherosclerosis*, 188(1): 51-8
14. **Steffens S**, Burger F, Pelli G, Dean Y, Elson G, Kosco-Vilbois M, Chatenoud L, Mach F (2006). *Short-term treatment with CD3 antibody reduces the development and progression of atherosclerosis in mice*. *Circulation*, 114(18):1977-84
15. Braunersreuther V, Zerneck A, Arnaud C, Liehn EA, **Steffens S**, Shagdarsuren E, Bidzhekov K, Burger F, Pelli G, Luckow B, Mach F, Weber C (2007). *CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice*. *Arteriosclerosis, Thrombosis and Vascular Biology*, 27(2):373-9
16. Montecucco F, **Steffens S**, Burger F, Da Costa A, Bianchi G, Bertolotto M, Mach F, Dallegri F, Ottonello L (2008). *Tumor necrosis factor-alpha (TNF-alpha) induces neutrophil migration to the CC chemokine CCL3 (MIP-1 alpha) through defined signaling pathways*. *Cellular Signalling*, 20(3):557-68
17. Montecucco F, Burger F, Mach F, **Steffens S** (2008). *The CB₂ cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways*. *American Journal of Physiology – Heart and Circulatory Physiology*, 294(3): H1145-55
18. Braunersreuther V, **Steffens S**, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F (2008). *A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice*. *Arteriosclerosis, Thrombosis and Vascular Biology*, 28(6):1090-6
19. Montecucco F*, **Steffens S***, Burger F, Mach F (2008). *C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes*. *Journal of Leukocyte Biology*, 84(4):1109-19 ***Equal first author contribution**
20. Montecucco F, Burger F, Pelli G, Poku NK, Berlier C, **Steffens S**, Mach F (2009). *Statins inhibit C-reactive protein (CRP)-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes*. *Rheumatology*, 48(3):233-42
21. Montecucco F*, Matias I*, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther V, Mach F, **Steffens S#**, Di Marzo V# (2009). *Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis*. *Atherosclerosis*, 205(2):433-41 ***Equal first/#last author contribution**

22. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F and **Steffens S** (2009). *CB₂ cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion*. Journal of Molecular and Cellular Cardiology, 46(5):612-20
23. Braunersreuther V, Pellieux C, Pelli G, Burger F, **Steffens S**, Montessuit C, Weber C, Proudfoot A, Mach F, Arnaud C (2010). *Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice*. Journal of Molecular and Cellular Cardiology, 48(4):789-98
24. Montecucco F, Lenglet S, Bertolotto M, Pelli G, Gayet-Ageron A, Palombo D, Pane B, Spinella G, **Steffens S**, Raffaghello L, Pistoia V, Ottonello L, Pende A, Dallegri F, Mach F (2010). *Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke*. Stroke, 41(7):1394-404
25. Thomas A, Deglon J, Lenglet S, Mach F, Mangin P, Wolfender J-L, **Steffens S**, Staub C (2010). *High-Throughput Phospholipidic Fingerprinting by Online Desorption of Dried Spots and Quadrupole-Linear Ion Trap Mass Spectrometry: Evaluation of Atherosclerosis Biomarkers in Mouse Plasma*. Analytical Chemistry, 82(15):6687-94
26. Frossard JL, Lenglet S, Montecucco F, **Steffens S**, Galan K, Pelli G, Spahr L, Mach F, Hadengue A (2011). *Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis associated lung injury*. Journal of Clinical Pathology, 64(5): 387-93
27. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, **Steffens S**, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH (2011). *Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity*. European Heart Journal, 32(11): 1369-78
28. Montecucco F[#], Di Marzo V[#], Da Silva RF, Vuilleumier N, Capettini L, Lenglet S, Pagano S, Piscitelli F, Quintao S, Maia Bertolotto M, Pelli G; Galan K, Pilet L, Kuzmanovic K, Burger F, Pane B, Spinella G, Braunersreuther V, Pende A, Palombo D, Dallegri F, Roux-Lombard P, Santos RAS, Stergiopoulos N, **Steffens S***, Mach F* (2012). *The activation of the cannabinoid receptor type 2 (CB₂) is associated with a reduction of atherosclerotic plaque vulnerability in humans and mice*. European Heart Journal, 33(7): 846-56 **#Equal first/*last author contribution**
29. Molica F, Matter CM, Burger F, Pelli G, Zimmer A, Pacher P, **Steffens S** (2012). *The CB₂ cannabinoid receptor is protective against balloon-induced neointima formation*. American Journal of Physiology – Heart and Circulatory Physiology, 302(5): H1064-74
30. Lenglet S, Thomas A, Soehnlein O, Montecucco F, Burger F, Pelli G, Galan K, Cravatt B, Staub C, **Steffens S** (2013). *Fatty Acid Amide Hydrolase Deficiency Enhances Intraplaque Neutrophil Recruitment in Atherosclerotic Mice*. Arteriosclerosis, Thrombosis and Vascular Biology, 33:215-223
31. Molica F, Burger F, Thomas A, Staub C, Tailleux A, Staels B, Pelli G, Zimmer A, Cravatt B, Matter CM, Pacher P, **Steffens S** (2013). *Endogenous cannabinoid receptor CB₁*

activation promotes vascular smooth-muscle cell proliferation and neointima formation. Journal of Lipid Research, 54:1360-1368

32. Fraga-Silva RA, Costa-Fraga FP, Montecucco F, Faye Y, Savergnini SQ, Lenglet S, Mach F, **Steffens S**, Stergiopoulos N, dos Santos RA, da Silva RF (2013). Treatment with CB2 agonist JWH-133 reduces histological features associated with erectile dysfunction in hypercholesterolemic mice. Clin Dev Immunol, 2013:263846.
33. Nencioni A, da Silva RF, Fraga-Silva RA, **Steffens S**, Fabre M, Bauer I, Caffa I, Magnone M, Sociali G, Quercioli A, Pelli G, Lenglet S, Galan K, Burger F, Vázquez Calvo S, Bertolotto M, Bruzzone S, Ballestrero A, Patrone F, Dallegri F, Santos RA, Stergiopoulos N, Mach F, Vuilleumier N, Montecucco F (2014). *Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.* Thrombosis Haemostasis, 111(2):308-22
34. Ring L, Neth P, Weber C, **Steffens S**, Faussner A (2014). *B-catenin dependent pathway activation by both promiscuous “canonical” WNT3a-, and specific “noncanonical” WNT4- and WNT5a-FZD receptor combinations with strong differences on LRP5 or LRP6 dependency.* Cell Signal, 26(2):260-7
35. Akhtar S, Hartmann P, Karshovska E, Rinderknecht FA, Subramanian P, Gremse F, Grommes J, Jacobs M, Kiessling F, Weber C, **Steffens S**, Schober A (2015). *Endothelial Hypoxia-Inducible Factor-1 α Promotes Atherosclerosis and Monocyte Recruitment by Upregulating MicroRNA-19a.* Hypertension, 66(6):1220-6.
36. Alard JE, Ortega-Gomez A, Wichapong K, Bongiovanni D, Horckmans M, Megens RTA, Leoni G, Ferraro B, Rossaint J, Paulin N, Hinkel R, Blanchet X, Gaillard F, D’Amico M, von Hundelshausen P, Zarbock A, Scheiermann C, Hackeng TM, **Steffens S**, Kupatt C, Nicolaes GAF, Weber C, Soehnlein O (2015). *Recruitment of classical monocytes can be inhibited by disturbing heteromers of neutrophil HNP1 and platelet CCL5.* Sci Transl Med., 7(317):317ra196
37. Hartmann P, Zhou Z, Natarelli L, Wei Y, Nazari-Jahantigh M, Zhu M, Grommes J, **Steffens S**, Weber C, Schober A (2016). *Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4.* Nature Communications, 7:10521
38. Schloss MJ, Horckmans M, Nitz K, Duchene J, Drechsler M, Bidzhekov K, Scheiermann C, Weber C, Soehnlein O, **Steffens S** (2016). *The time-of-day of myocardial infarction onset affects healing through oscillations in cardiac neutrophil recruitment.* EMBO Molecular Medicine, 8(8):937-48
39. Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M, Weber C, Soehnlein O, **Steffens S** (2017). *Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype.* European Heart Journal, 38(3):187-197
 ***Editorial by Froderman & Nahrendorf; top cited article

40. Zahedi F, Nazari-Jahantigh M, Zhou Z, Subramanian P, Wei Y, Grommes J, Offermanns S, **Steffens S**, Weber C, Schober A (2017). *Dicer generates a microRNA regulatory network in smooth muscle cells during vascular repair that limits neointima formation*. Cellular and Molecular Life Sciences, 74(2):359-372
41. Nicolaou A, Zhao Z, Northoff BH, Sass K, Herbst A, Kohlmeier A, Chalaris A, Wolfrum C, Weber C, **Steffens S**, Rose-John S, Teupser D, Holdt LM (2017). *Adam17-Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in mice*. Arteriosclerosis, Thrombosis and Vascular Biology, 37(2):247-257
42. Van der Vorst E[#], Zhao Z[#], Rami M, Holdt LM, Teupser D, **Steffens S***, Weber C* (2017). *Contrasting effects of myeloid and endothelial ADAM17 on atherosclerosis development*. Thrombosis Haemostasis, 117 (3):644-646 **#Equal first/last author contribution**
43. Rinne P, Rami M, Nuutinen S, Lyytikäinen L-P, Oksala N, Ring L, Cai M, Hruby VJ, Lehtimäki T, Weber C, **Steffens S** (2017). *Melanocortin 1 receptor signaling regulates cholesterol transport in macrophages*. Circulation, 136:83-97
44. Schloss MJ; Hilby M, Nitz K, Guillamat Prats R, Ferraro B, Leoni G, Soehnlein O, Kessler T, Horckmans M, Luckow B, Weber C, Duchene J, **Steffens S** (2017). *Ly6C^{high} monocytes oscillate in the heart during homeostasis and after myocardial infarction*. Arteriosclerosis, Thrombosis and Vascular Biology, 37(9):1640-1645.
45. Nicolaou A, Northoff BH, Zhao Z, Kohlmeier A, Sass K, Rose-John S, **Steffens S**, Weber C, Teupser D, Holdt LM (2018). *The ADAM17 metalloproteinase maintains arterial elasticity*. Thrombosis Haemostasis, 118(1):210-213
46. Horckmans M, Bianchini M, Santovito D, Megens RTA, Springael JY, Negri I, Vacca M, Eusanio M, Moschetta A, Weber C, Duchene J, **Steffens S** (2018). *Pericardial adipose tissue regulates granulopoiesis, fibrosis and cardiac function after myocardial infarction*. Circulation 137(9):948-960
***Research Highlight in Nature Reviews Cardiology, March 2018
47. Rinne P, Kadiri JJ, Velasco-Delgado M, Nuutinen S, Viitala M, Hollmén M, Rami M, Savontaus E*, **Steffens S*** (2018). *Melanocortin 1 Receptor Deficiency Promotes Atherosclerosis in Apolipoprotein E-/- Mice*. Arteriosclerosis, Thrombosis and Vascular Biology, 38: 313-323 ***Equal last author contribution**
48. Rami M, Guillamat-Prats R*, Rinne P*, Salvermoser M, Ring L, Bianchini M, Blanchet X, Megens R, Döring Y, Walzog B, Soehnlein O, Weber C, Faussner A, **Steffens S** (2018). *Chronic intake of the selective serotonin reuptake inhibitor fluoxetine enhances atherosclerosis*. Arteriosclerosis, Thrombosis and Vascular Biology, 38: 1007-1019
***Equal second author contribution**
***Editorial by Wang & Eitzman
49. Rinne P*, Guillamat-Prats R*, Rami M, Bindila L, Ring L, Lyytikäinen LP, Raitoharju E, Oksala N, Lehtimäki T, Weber C, van der Vorst EPC, **Steffens S** (2018). *Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation*. Arteriosclerosis, Thrombosis and Vascular Biology. Nov;38(11):2562-2575. ***Equal first author contribution**

50. Schloss MJ*, Horckmans M*, Guillaumat-Prats R, Hering D, Lauer E, Lenglet S, Weber C, Thomas A, **Steffens S** (2019). *2-arachidonoylglycerol mobilizes myeloid cells and worsens heart function after acute myocardial infarction*. Cardiovascular Research. 115(3):602-613 ***Equal first author contribution**
***Editorial by Beguier & Epelman
51. Guillaumat-Prats R*, Rami M*, Ring L*, Rinne P, Lauer E, Lenglet S, Thomas A, Pagano S, Vuilleumier N, Caravatt BF, Weber C, Faussner A, **Steffens S** (2019). *Deficiency of monoacylglycerol lipase enhances IgM plasma levels and limits atherogenesis in a CB2-dependent manner*. Thrombosis Haemostasis 119(2):348-351 ***Equal first author contribution**
52. Yin C#, Susanne Ackermann S#, Zhe Ma Z, Mohanta SK, Zhang C1, Li Y, Nietzsche S, Westermann M, Peng L, Hu D, Bontha SV, Srikakulapu P, Beer M, Megens RTA, **Steffens S**, Hildner M, Halder LD, Eckstein HH, Pelisek J, Herms J, Roeber S, Arzberger T, Borodovsky A, Habenicht L, Binder CJ, Weber C*, Zipfel PF*, Skerka C3*, Habenicht AJR* (2019). *ApoE attenuates unresolvable inflammation by complex formation with activated C1q*. Nature Medicine 25(3):496-506 #**Equal first/last author contribution**
***Comment by G. Fredman in Nature Reviews Cardiology, March 2019
53. Bianchini M, Duchêne J, Santovito D, Schloss MJ, Evrard M, Winkels H, Aslani M, Mohanta SK, Horckmans M, Blanchet X, Lacy M, von Hundelshausen P, Atzler D, Habenicht A, Gerdes N, Jaroslav Pelisek J, Ng LG, **Steffens S**, Weber C, Megens RTA (2019). *CD274/PD-L1 marks non-classical monocytes to unveil new features of their origin and immunoregulatory function*. Science Immunology 4(36). pii: eaar3054
54. Sager HB, Husser O, **Steffens S**, Laugwitz KL, Schunkert H, Kastrati A, Ndrepepa G, Kessler T (2019). *Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction*. Journal of Translational Medicine 17(1):180

Review articles, peer-reviewed

1. **Steffens S**, Mach F (2004). *Inflammation and atherosclerosis*. Herz 29(8):741-8
2. **Steffens S**, Mach F (2004). *Antiinflammatory properties of statins*. Seminars in Vascular Medicine, 4: 417-22
3. **Steffens S**, Mach F (2006). *Toward a therapeutic use of cannabinoid CB(2) receptor in atherosclerosis*. Medecine Science (Paris), 22(1): 7-9
4. **Steffens S**, Mach F (2006). *Towards a therapeutic use of selective cannabinoid receptor ligands for atherosclerosis*. Future Cardiology, 2(1): 49-53
5. **Steffens S**, Mach F (2006). *Drug insight: immunomodulatory effects of statins-potential benefits for renal patients?* Nature Clinical Practice Nephrology, 2(7):378-87

6. **Steffens S**, Mach F (2006). *Cannabinoid receptors in atherosclerosis*. *Current Opinion in Lipidology*, 17(5): 519-26
7. Braunersreuther V, Mach F, **Steffens S** (2007). *The specific role of chemokines in atherosclerosis*. *Thrombosis and Haemostasis*, 97(5): 714-21
8. Mach F, Montecucco F, **Steffens S** (2008). *Cannabinoid receptors in acute and chronic complications of atherosclerosis*. *British Journal of Pharmacology*, 153(2): 290-8
9. Montecucco F, **Steffens S**, Mach F (2007). *The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability?* *Clinical & Developmental Immunology*, 2007: 75805
10. Mach F, **Steffens S** (2008). *The role of the endocannabinoid system in atherosclerosis*. *Journal of Neuroendocrinology*, 20(Suppl 1): 53-7
11. Montecucco F, **Steffens S**, Mach F (2008). *Insulin resistance: a pro-atherosclerotic condition associated with lipid-induced signaling dysfunction?* *Mediators of Inflammation*, 2008: 767623
12. Mach F, Montecucco F, **Steffens S** (2009). *Blockage of the endocannabinoid system with rimonabant in cardiovascular risk*. *Pharmacological Reports*, 61(1): 13-21
13. Pacher P, **Steffens S** (2009). *The emerging role of the endocannabinoid system in cardiovascular disease*. *Seminars in Immunopathology*, 31(1): 63-77
14. **Steffens S***, Montecucco F*, Mach F (2009). *The inflammatory response as a target to reduce myocardial ischemia and reperfusion injury*. *Thrombosis Hemostasis*, 102(2): 240-7 ***Equal first author contribution**
15. Tuma R, **Steffens S** (2012). *Targeting the endocannabinoid system to limit myocardial and cerebral ischemic and reperfusion injury*. *Current Pharmaceutical Biotechnology*, 13(1): 46-58
16. Thomas A, Lenglet S, Mach F, Déglon J, Mangin P, Chaurand P, Wolfender J-L, **Steffens S**, Staub C (2011). *Mass spectrometry for evaluation of cardiovascular diseases based on proteomic and lipidomic strategies*. *Thrombosis and Hemostasis*, 106(1):20-33
17. **Steffens S** and Pacher P (2012). *Targeting cannabinoid receptor CB₂ in cardiovascular disorders: promises and controversies*. *British Journal of Pharmacology*, 167(2):313-23
18. Asrih M, **Steffens S** (2013). *Emerging role of epigenetics and miRNA in diabetic cardiomyopathy*. *Cardiovascular Pathology*, 22(2):117-25
19. Michel Monigadon D, **Steffens S**, Molica F, Mach F, Montecucco F (2012). *Update on the endocannabinoid-mediated regulation of gelatinase release in arterial wall physiology and atherosclerotic pathophysiology*. *Expert Review of Cardiovascular Therapy*, 10(12):1481-6

20. Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, **Steffens S** (2015). *Adipokines at the crossroad between obesity and cardiovascular disease*. *Thrombosis Haemostasis*,113(3):553-66.
21. **Steffens S**, Pacher P. *The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism?* *Curr Drug Targets*. 2015;16(4):334-41.
22. Soehnlein O, **Steffens S**, Hidalgo A, Weber C (2017). *Neutrophils as protagonists and targets in chronic inflammation*. *Nat Rev Immunol* 17(4): 248-261.
23. **Steffens S**, Winter C, Schloss M, Hidalgo A, Weber C, Soehnlein O (2017). *Circadian control of inflammatory processes in atherosclerosis and its complications*. *Arteriosclerosis, Thrombosis and Vascular Biology* 37(6):1022-1028.
24. Pacher P, **Steffens S**, Hasko G, Schindler T, Kunos G (2018). *Cardiovascular effects of endocannabinoids, marijuana and synthetic cannabinoids: the good, the bad and the ugly*. *Nat Rev Cardiol* 15(3):151-166
25. Guillaumat-Prats R, Rami M, Herzig S, **Steffens S** (2019). *Endocannabinoid signaling in atherosclerosis and related metabolic complications*. *Thrombosis and Haemostasis* 119(4):567-575
26. Puhl SL, **Steffens S** (2019). *Neutrophils in post-myocardial infarction inflammation: damage versus resolution?* *Frontiers in Cardiovascular Medicine* 18;6:25
27. Lutgens E, Atzler D, Döring Y, Duchene J, **Steffens S**, Weber C (2019). *Immunotherapy for cardiovascular disease*. *European Heart Journal* 40(48):3937-3946.

Position papers

1. Kwak BR, Bäck M, Bochaton-Piallat ML, Caligiuri G, Daemen MJAP, Davies PF, Hofer IE, Holvoet P, Jo H, Krams R, Lehoux S, Monaco C, **Steffens S**, Virmani R, Weber C, Wentzel JJ, Evans PC (2014). *Biomechanical Factors in Atherosclerosis - mechanisms and clinical implications (Position paper from the ESC Working Group Atherosclerosis and Vascular Biology)* *European Heart Journal* 2014, 35(43):3013-20, 3020a-3020d
2. Hofer IE*, **Steffens S***, Ala-Korpela M, Bäck M, Badimon L, Bochaton-Piallat ML, Boulanger CM, Caligiuri G, Dimmeler S, Egido J, Evans PC, Guzik T, Kwak BR, Landmesser U, Mayr M, Monaco C, Pasterkamp G, Tuñón J, Weber C; ESC Working Group Atherosclerosis and Vascular Biology (2015). *Novel methodologies for biomarker discovery in atherosclerosis*. *European Heart Journal*, 36(39):2635-42 ***Equal first author contribution**
3. Weber C, Shantsila E, Hristov M, Caligiuri G, Guzik T, Heine G, Hofer I, Monaco C, Peter K, Rainger E, Siegbahn A, **Steffens S**, Wojta J, Lip GYH; Joint position paper of the ESC Working Group Atherosclerosis and Vascular Biology and ESC Working Group on Thrombosis (2016). *Role and analysis of monocyte subsets in cardiovascular disease*. *Thrombosis and Haemostasis*, 116(4):626-37

4. Tuñón J*, Bäck M*, Badimon L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Francis SE, Ketelhuth DFJ, Lutgens E, Matter CM, Monaco C, **Steffens S**, Stroes E, Vindis C, Weber C, Hofer IE, ESC Working Group Atherosclerosis and Vascular Biology (2018) *Interplay between hypercholesterolemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice*. European Journal of Preventive Cardiology, 25(9):948-955.

***Equal first author contribution**

5. Caporali A, Bäck M, Daemen MJ, Hofer IE 5, Jones EA, Lutgens E, Matter CM, Bochaton-Piallat ML, Siekmann AF, Sluimer JC, **Steffens S**, Tuñón J, Vindis C, Wentzel JJ, Ylä-Herttuala S, Evans PC (2018). *Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working group on Atherosclerosis and Vascular Biology*. Cardiovascular Research, 114(11):1411-1421.
6. Tuñón J, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Hofer IE, Ketelhuth DFJ, Lutgens E, Matter CM, Monaco C, **Steffens S**, Stroes E, Vindis C, Weber C, Bäck M (2019). *Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology*. Cardiovascular Research, 115(1):10-19.

Editorials

1. **Steffens S**, Mach F (2008). *Adiponectin and adaptive immunity: Linking the bridge from obesity to atherogenesis*. Circulation Research, 102(2): 140-2
2. **Steffens S** (2014). *Fine tuning effector and regulatory T-cell dynamics: a novel tool for plaque regression?* Cardiovascular Research, 102(1):3-5
3. **Steffens S** (2016). *MI signature mediators in atheroma-derived single cell secretome of symptomatic plaques*. Thrombosis and Hemostasis, May 2;115(5):871
4. **Steffens S**, Weber C (2019). *Immunotherapy for atherosclerosis – novel concepts*. Thrombosis and Hemostasis 119(4):515-516

Other publications

1. **Steffens S** (1997). *Identification of an RNA-dependent RNA-polymerase of pestiviruses*. Diploma thesis, Justus-Liebig-Universität, Fachbereich Biologie, Giessen, Deutschland
2. **Steffens S** (2002). *Development of a tumorspecific suicide gene therapy for neuroblastomas*. PhD thesis, Heinrich-Heine-Universität Düsseldorf, Deutschland
3. **Steffens S** (2006). *Cannabinoids for therapeutic use in atherosclerosis*. Kardiovaskuläre Medizin, 9: 268-73

4. **Steffens S**, Mach F (2007). *Effets du système cannabinoïde sur les maladies cardiovasculaires*. Cardiovasc, 6:10-12
5. Montecucco F, **Steffens S**, Mach F (2007). *Inflammation as a coronary risk factor*. ARS Medici, 23: 1145-52
6. Mach F, Montecucco F, **Steffens S** (2008). *Role of the endocannabinoid system in atherosclerosis*. CMR Journal, (Official Journal of the International Chair on Cardiometabolic Risk)
7. **Steffens S** (2012). *The role of the endocannabinoid system in the pathogenesis of atherosclerosis*. Habilitation thesis (privat docent), Medical Faculty, University of Geneva, Switzerland